These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 8994509)

  • 1. Bridging study of S12024 in 53 in-patients with Alzheimer's disease.
    Allain H; Neuman E; Malbezin M; Salzman V; Guez D; Wesnes K; Gandon JM
    J Am Geriatr Soc; 1997 Jan; 45(1):125-6. PubMed ID: 8994509
    [No Abstract]   [Full Text] [Related]  

  • 2. Application of population pharmacokinetics to the phase II development of an anti-Alzheimer's disease compound, S12024.
    Laveille C; Lachaud-Pettiti V; Neuman E; Jochemsen R
    J Clin Pharmacol; 1998 Apr; 38(4):315-23. PubMed ID: 9590458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed matching-to-sample performance during a double-blind trial of tacrine (THA) and lecithin in patients with Alzheimer's disease.
    Perryman KM; Fitten LJ
    Life Sci; 1993; 53(6):479-86. PubMed ID: 8341134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tacrine in Alzheimer's disease.
    Davies B; Andrewes D; Stargatt R; Ames D; Tuckwell V; Davis S
    Lancet; 1989 Jul; 2(8655):163-4. PubMed ID: 2567933
    [No Abstract]   [Full Text] [Related]  

  • 6. Tacrine in Alzheimer's disease. Time course of changes in cognitive function and practice effects.
    Eagger S; Morant N; Levy R; Sahakian B
    Br J Psychiatry; 1992 Jan; 160():36-40. PubMed ID: 1544011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatidylserine in the treatment of Alzheimer's disease: results of a multicenter study.
    Amaducci L
    Psychopharmacol Bull; 1988; 24(1):130-4. PubMed ID: 3290936
    [No Abstract]   [Full Text] [Related]  

  • 8. APOE genotyping and response to drug treatment in Alzheimer's disease.
    Richard F; Helbecque N; Neuman E; Guez D; Levy R; Amouyel P
    Lancet; 1997 Feb; 349(9051):539. PubMed ID: 9048794
    [No Abstract]   [Full Text] [Related]  

  • 9. Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
    Holmes C; Wilkinson D; Dean C; Clare C; El-Okl M; Hensford C; Moghul S
    Int J Geriatr Psychiatry; 2007 Apr; 22(4):380-1. PubMed ID: 17380475
    [No Abstract]   [Full Text] [Related]  

  • 10. [Naftidrofuryl in patients with multi-infarct dementia and Alzheimer's disease].
    Grossmann W; Standl A; May U
    Vasa Suppl; 1988; 24():48-55. PubMed ID: 3212603
    [No Abstract]   [Full Text] [Related]  

  • 11. A pilot study of serotonergic system responsivity in Alzheimer's disease.
    Lawlor BA; Mellow AM; Sunderland T; Hill JL; Murphy DL
    Psychopharmacol Bull; 1988; 24(1):127-9. PubMed ID: 3290935
    [No Abstract]   [Full Text] [Related]  

  • 12. Effects of 4-aminopyridine in elderly patients with Alzheimer's disease.
    Wesseling H; Agoston S; Van Dam GB; Pasma J; DeWit DJ; Havinga H
    N Engl J Med; 1984 Apr; 310(15):988-9. PubMed ID: 6366565
    [No Abstract]   [Full Text] [Related]  

  • 13. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Velnacrine for the treatment of Alzheimer's disease: a double-blind, placebo-controlled trial. The Mentane Study Group.
    Zemlan FP
    J Neural Transm (Vienna); 1996; 103(8-9):1105-16. PubMed ID: 9013398
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression.
    Reifler BV; Teri L; Raskind M; Veith R; Barnes R; White E; McLean P
    Am J Psychiatry; 1989 Jan; 146(1):45-9. PubMed ID: 2643356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease.
    Devanand DP; Marder K; Michaels KS; Sackeim HA; Bell K; Sullivan MA; Cooper TB; Pelton GH; Mayeux R
    Am J Psychiatry; 1998 Nov; 155(11):1512-20. PubMed ID: 9812111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of loratadine/montelukast on vigilance and alertness task performance in a simulated cabin environment.
    Valk PJ; Simons M
    Adv Ther; 2009 Jan; 26(1):89-98. PubMed ID: 19089321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine.
    Davis KL; Mohs RC
    Am J Psychiatry; 1982 Nov; 139(11):1421-4. PubMed ID: 6753611
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-blind placebo-controlled study of velnacrine in Alzheimer's disease.
    Zemlan FP; Keys M; Richter RW; Strub RL
    Life Sci; 1996; 58(21):1823-32. PubMed ID: 8637408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cholinergic system and constructional praxis: a further study of physostigmine in Alzheimer's disease.
    Muramoto O; Sugishita M; Ando K
    J Neurol Neurosurg Psychiatry; 1984 May; 47(5):485-91. PubMed ID: 6736979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.